에 대한 최신 뉴스 Cencora (NYSE:COR) 주식

Cencora

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

CoreSite Realty

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

Equities

BEKE

BGNE

LULU

MSTR

NDSN

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 내셔널 그리드 트랜스코(NYSE:NGG)가 70억 파운드의 자본금을 늘리고 연간 매출 결과가 전년 대비 감소했다고 보고한 후 주각가 17.1% 급락했다. 

지난주 최악의 성과를 보인 룰루레몬 애틀라티카 포함 10개의 대형주 (5월 19일-5월 26일)

Cencora Inc

Coreto

GLOBAL CORD BLOOD CORP by Global Cord Blood Corporation

Global Cord Blood Corp

CORNWALL RESOURCES INC by Cornwall Resources, Inc.

cVault.finance

Core - United States dollar

Cordia Corp

CorEnergy Infrastructure Trust Inc Depositary Shares each representing 1/100th of a whole share of Series A Preferred Stock

Teucrium Corn Fund ETV

iShares International Country Rotation Active ETF

Pimco Investment Grade Corporate Bond Index Exchange-Traded Fund

CorEnergy Infrastructure Trust Inc OM

CorEnergy Infrastructure Trust Inc

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

Volatility Shares Trust 2x Corn ETF

Core Scientific Inc

Core Scientific Inc Ordinary Shares - Class A

Core Scientific, Inc. - Tranche 1 Warrants

Core Scientific, Inc. - Tranche 2 Warrants

<a href="https://www.youtube.com/watch?v=fjFI9jPVh-A" title="https://www.youtube.com/watch?v=fjFI9jPVh-A">https://www.youtube.com/watch?v=fjFI9jPVh-A</a>

Biotech

Macro Economic Events

Global

Economics

General

President-Elect Donald J. Trump Says 'We're Going To Knock Out The Middlemen' Who Are Keeping Drug Prices High

Wells Fargo analyst Eric Luebchow maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Equal-Weight and lowers the price target from $249 to $237.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Cencora, Lowers Price Target to $237

Cencora's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) short percent of float has risen 3.18% since its last report. The company recently reported that it has 10.11 million shares sold short, which is 7.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cencora Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733938218_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cencora has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cencora's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cencora's peer group average for short interest as a percentage of float is 4.97%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(COR) - Analyzing Cencora's Short Interest

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 9.55% on an annualized basis producing an average annual return of 23.33%. Currently, Cencora has a market capitalization of $46.80 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $278.98 today based on a price of $242.13 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733761867_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today

Disclosed on November 26, Steven H Collis, Executive Chairman at Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: Collis opted to sell 50,000 shares of Cencora, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001140859/000114085924000179//Archives/edgar/data/1140859/000114085924000179/0001140859-24-000179-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The transaction's total worth stands at $12,198,750.
Cencora shares are trading down 0.02% at $248.41 at the time of this writing on Wednesday morning.
<h3>Unveiling the Story Behind Cencora</h3>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>Cencora: A Financial Overview</h3>
Revenue Growth: Cencora displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 6.48%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 3.15%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Cencora's EPS reflects a decline, falling below the industry average with a current EPS of 0.02.
</li>
</ul>
Debt Management: Cencora's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.58, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 32.99, Cencora's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.17 is lower than the industry average, implying a discounted valuation for Cencora's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Cencora's EV/EBITDA ratio stands at 14.62, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001140859">Check Out The Full List Of Cencora's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Decision: Steven H Collis Offloads $12.20M Worth Of Cencora Stock

Cencora's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) short percent of float has risen 3.45% since its last report. The company recently reported that it has 9.96 million shares sold short, which is 6.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cencora Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732203915_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cencora has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cencora's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cencora's peer group average for short interest as a percentage of float is 5.37%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Cencora's Recent Short Interest

Baird analyst David Rodgers maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and raises the price target from $287 to $292.

Baird Maintains Outperform on Cencora, Raises Price Target to $292

UBS analyst Kevin Caliendo maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Buy and raises the price target from $275 to $285.

UBS Maintains Buy on Cencora, Raises Price Target to $285

Barclays analyst Stephanie Davis maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Overweight and raises the price target from $263 to $290.

Barclays Maintains Overweight on Cencora, Raises Price Target to $290

During the last three months, 6 analysts shared their evaluations of Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $270.83, a high estimate of $287.00, and a low estimate of $245.00. Experiencing a 0.86% decline, the current average is now lower than the previous average price target of $273.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1730988020_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Cencora among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Belton</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>John Belton</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$287.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cencora. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cencora compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cencora's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Cencora's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cencora analyst ratings.</a>
<h2>All You Need to Know About Cencora</h2>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>Financial Insights: Cencora</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Cencora displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 10.9%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cencora's net margin is impressive, surpassing industry averages. With a net margin of 0.65%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cencora's ROE stands out, surpassing industry averages. With an impressive ROE of 48.15%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.74%, the company showcases effective utilization of assets.
Debt Management: Cencora's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.11, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Cencora Stock: Analyst Perspectives (6 Ratings)

Evercore ISI Group analyst John Belton maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and raises the price target from $250 to $285.

Evercore ISI Group Maintains Outperform on Cencora, Raises Price Target to $285

An &#8220;everything rally&#8221; powered Wall Street on Wednesday after the 2024 election results, with Donald Trump emerging as the clear presidential winner. The Republican Party reclaimed control of the Senate, while the House of Representatives leans Republican <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41778433/s-p-500-dow-hit-record-highs-after-trump-win-fear-index-drops-20">but remains undecided.</a>
The major U.S. equity indices – the S&amp;P 500, Dow Jones Industrial Average, and Nasdaq 100 – surged to record highs in early trading, as investor optimism grew on expectations of more favorable tax policies. 
The S&amp;P 500, Nasdaq, and Dow posted gains of 2.3%, 2.4%, and 3.3%, respectively.
However, the real standouts were small caps and bank stocks, with investors turning to domestic businesses and U.S. banks in anticipation of potential tariff protections and further financial deregulation. 
The Russell 2000 jumped 5.5%, marking its largest single-day increase in two years. 
Large-cap bank stocks climbed 6%, while regional banks tracked by the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) soared 13%—both seeing their biggest one-day gains since November 2020, when the first COVID-19 vaccine was announced.
Clean energy stocks were among the day's worst performers, with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) plunging 11% for its steepest drop since March 2020, as investors braced for potential rollbacks on green initiatives under the Trump administration.
In the foreign exchange market, the U.S. dollar initially rallied nearly 2% before paring gains to 1.4% as traders awaited a Federal Reserve interest rate cut on Thursday.
Treasury yields spiked as expectations rose for larger budget deficits under Republican fiscal policies and higher inflation due to potential tariffs. The 10-year Treasury yield climbed 14 basis points to 4.41%, reaching a four-month high.
Gold prices fell 2.8%, silver dropped over 4%, while natural gas rose 3.8%. Oil prices remained steady.
In the cryptocurrency market, risk appetite thrived, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rising over 8% to reach a record high of $75,000. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) gained 10%, and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) surged 14%, the strongest performance among the top 10 cryptocurrencies.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, Sectors</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,388.20</td>
<td>5.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,739.86</td>
<td>3.6%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,740.09</td>
<td>2.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,922.98</td>
<td>2.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Sector</th>
<th>1-day % chg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financials</td>
<td>6.0%</td>
</tr>
<tr>
<td>Energy</td>
<td>4.0%</td>
</tr>
<tr>
<td>Industrials</td>
<td>3.9%</td>
</tr>
<tr>
<td>Cons. Discretionary</td>
<td>2.9%</td>
</tr>
<tr>
<td>Technology</td>
<td>2.7%</td>
</tr>
<tr>
<td>Communications</td>
<td>1.9%</td>
</tr>
<tr>
<td>Materials</td>
<td>1.8%</td>
</tr>
<tr>
<td>Health Care</td>
<td>0.3%</td>
</tr>
<tr>
<td>Utilities</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Cons. Staples</td>
<td>-1.7%</td>
</tr>
<tr>
<td>Real Estate</td>
<td>-3.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 2.4% to $590.30.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rallied 3.5% to $437.05.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 2.5% to $504.69.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) spiked 5.6% to $236.23.</li>
<li>The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, rising 6%. The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) lagged, down 3.3%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports were: 
<ul>
<li>Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), up 2%, </li>
<li>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), up 1.8%, </li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), down 22%, </li>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), up 12%,</li>
<li>DBA Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>), up 5.8%, </li>
<li>American Electric Power Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>), down 3%, </li>
<li>Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), up 5.5%, </li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>), up 10.7%, </li>
</ul>
Major companies moving in reaction to election results were: 
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), up 14.8%, </li>
<li>Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), up 14.4%, </li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), up 13.1%, </li>
<li>Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), up 13.1%, </li>
<li>The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), up 12.9%. </li>
</ul>
The rallies in the stock and crypto markets drove shares of Robinhood Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) up by 18% and 26%, respectively.
Major losers among clean energy stocks included Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) and First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), down 16.7% and 10.5%, respectively. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41781115/stock-of-the-day-trump-media-technology-hits-resistance-reverses-and-trends-lower">Stock Of The Day: Trump Media &amp; Technology Hits Resistance, Reverses And Trends Lower</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Mid Cap

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Politics

Forex

Small Cap

Federal Reserve

Tech

ETFs

$BTC

$DOGE

$ETH

COIN

SPDR Dow Jones Industrial Average ETF Trust

ENPH

FSLR

HOOD

SMCI

TSLA

XLRE

Select Sector SPDR-Consumer Discretionary

Trump's Win Sends Indices To Record Highs; Financials, Small Caps Surge, Bitcoin Tops $75,000: What's Driving Markets Wednesday?

On Wednesday, Cencora, Inc.&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $77.65 billion</a>.&nbsp;&nbsp;
The sales jump reflects a 15.7% increase in revenue within U.S. Healthcare Solutions and a 5.5% increase in revenue within International Healthcare Solutions.
The company reported adjusted EPS of $3.34, up 16.8% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769243/cencora-reports-fiscal-2024-fourth-quarter-and-year-end-results" rel="noreferrer noopener">consensus of $3.22</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40694838/opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurer" rel="noreferrer noopener">Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers</a>
Concurrently, Cencora agreed to acquire Retina Consultants of America, a management services organization (MSO) of retina specialists, from Webster Equity Partners <a href="https://www.benzinga.com/pressreleases/24/11/b41769033/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america" target="_blank" rel="noreferrer noopener">for $4.6 billion</a>.
The Retina Consultants of America deal will add nearly 300 retina specialists to Cencora&#8217;s portfolio of physician management services.
Retina Consultants of America&#8217;s affiliated practices, physicians and management will retain a minority interest in Retina Consultants of America, with Cencora holding approximately 85% ownership in Retina Consultants of America upon closing.
Retina Consultants of America is a network of retina practices. The retina specialists and surgeons provide advanced care for macular degeneration, diabetic retinopathy, geographic atrophy, and among others.
Additionally, Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal years 2027 and 2028, subject to the successful completion of certain predefined business objectives.
Dividend: Cencora announced a quarterly dividend of $0.55 per share, up 8% from $0.51, payable November 29, to stockholders of record at the close of business on November 15.&nbsp;
Guidance: Cencora expects fiscal year 2025 adjusted EPS of $14.80-$15.10 compared to consensus of $13.64.
The company forecasts revenue growth of 7%-9%, with adjusted operating income growth of 5%-6.5%.
Cencora&#8217;s fiscal 2025 guidance does not currently include the impact of the Retina Consultants of America acquisition.
Price Action: COR stock is up 4.13% at $243.66 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41777466/cvs-health-stock-jumps-after-mixed-q3-earnings-takes-1-2-billion-restructuring-charges-hit" target="_blank" rel="noreferrer noopener">CVS Health Stock Jumps After Mixed Q3 Earnings, Takes $1.2 Billion Restructuring Charges Hit</a></li>
</ul>

Guidance

Dividends

Health Care

Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings

Cencora Forecasts 2025 Adjusted EPS Of $14.80-$15.10 Vs. $13.64 Est.

Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
<ul>
<li>Revenue growth to be in the range of 7 to 9 percent;
<ul>
<li>U.S. Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;</li>
<li>International Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;</li>
</ul>
</li>
<li>Adjusted diluted earnings per share to be in the range of $14.80 to $15.10.</li>
</ul>
Additional expectations include:
<ul>
<li>Adjusted operating income growth to be in the range of 5 to 6.5 percent;
<ul>
<li>U.S. Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;</li>
<li>International Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;</li>
</ul>
</li>
<li>Interest expense to be in the range of $150 million to $170 million;</li>
<li>Adjusted effective tax rate of approximately 21 percent;</li>
<li>Adjusted free cash flow to be in the range of $2.0 billion to $3.0 billion;</li>
<li>Capital expenditures to be approximately $600 million; and</li>
<li>Weighted average diluted shares outstanding to be approximately 196 million.</li>
</ul>

Cencora Has Introduced Its Full Fiscal Year 2025 Financial Guidance, Which Reflects Adjusted Operating Income Growth Of 5%-6.5% And Adjusted Diluted EPS Growth Of 8%-10%

The quarterly dividend of $0.55 per common share is payable November 29, 2024, to stockholders of record at the close of business on November 15, 2024.&nbsp;

Cencora Declared A Quarterly Dividend Of $0.55 Per Common Share, An 8% Increase In Its Quarterly Dividend Rate From $0.51 Per Common Share

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported quarterly earnings of $3.34 per share which beat the analyst consensus estimate of $3.22 by 3.73 percent. This is a 16.78 percent increase over earnings of $2.86 per share from the same period last year. The company reported quarterly sales of $79.05 billion which beat the analyst consensus estimate of $77.65 billion by 1.80 percent. This is a 14.70 percent increase over sales of $68.92 billion the same period last year.

Cencora Q4 2024 Adj EPS $3.34 Beats $3.22 Estimate, Sales $79.05B Beat $77.65B Estimate

Transaction Details
Cencora will acquire RCA for approximately $4.6 billion in cash, subject to a customary working capital and net-debt adjustment. RCA's affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally, Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal year 2027 and fiscal year 2028, subject to the successful completion of certain predefined business objectives.

Cencora Has Agreed To Acquire Retina Consultants Of America From Webster Equity Partners For Approximately $4.6B In Cash

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 7.66% on an annualized basis producing an average annual return of 21.48%. Currently, Cencora has a market capitalization of $46.09 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $269.09 today based on a price of $235.16 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729805410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today

A large exercise of company stock options by Steven H Collis, Executive Chairman at Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) was disclosed in a new SEC filing on October 23, as part of an insider exercise.
What Happened: Collis, Executive Chairman at Cencora, exercised stock options for 21,509 shares of COR stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001140859/000114085924000137//Archives/edgar/data/1140859/000114085924000137/0001140859-24-000137-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The exercise price of the options was $89.58 per share.
The latest update on Thursday morning shows Cencora shares down by 0.0%, trading at $234.52. At this price, Collis's 21,509 shares are worth $3,117,514.
<h3>Get to Know Cencora Better</h3>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>Key Indicators: Cencora's Financial Health</h3>
Positive Revenue Trend: Examining Cencora's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.9% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 3.25%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Cencora's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.44.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.11, caution is advised due to increased financial risk.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 25.44 is lower than the industry average, implying a discounted valuation for Cencora's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.17 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Cencora's EV/EBITDA ratio stands at 12.75, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001140859">Check Out The Full List Of Cencora's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: Steven H Collis Exercises Options At Cencora For $3.12M

TimesSquare U.S. Mid Cap Growth Q3 2024 Commentary

Cencora prices $1.8B debt offering

Mizuho assumed overage of Cencora (COR) with an Outperform rating and $280 price target. The company remains well-positioned to generate both EBIT ...

Cencora assumed with an Outperform at Mizuho

Mizuho analyst Steven Valiquette assumed coverage of Cardinal Health (CAH) with an Outperform rating and $139 price target. Cardinal has seen impro...

Cardinal Health assumed with an Outperform at Mizuho

Cencora ( ($COR) ) has issued an update. Cencora, Inc. has announced the pricing of $1.8 billion in senior notes in a public offering, with the pro...

Cencora Raises $1.8 Billion for Strategic Acquisition

Cencora: Competitive Advantages Defined

In a report released yesterday, Allen Lutz from Bank of America Securities assigned a Hold rating on Cencora (COR – Research Report), with a price ...

Cencora's Strategic Innovations Enhance Supply Chain Amidst Neutral Market Valuation

Cencora ( ($COR) ) has issued an announcement. Cencora, Inc. has successfully closed a $1.8 billion senior notes offering, comprised of $500 millio...

Cencora's Strategic Acquisition and Financial Maneuvering

Wells Fargo lowered the firm's price target on Cencora (COR) to $237 from $249 and keeps an Equal Weight rating on the shares. The firm updated est...

Cencora price target lowered to $237 from $249 at Wells Fargo

Moderna remains the most shorted among S&P 500 healthcare stocks in November

ARGX

CRWD

CTAS

CTLT

DASH

ESTC

ICON

MCHP

MRNA

ORLY

PINS

RGEN

ROST

SAIA

SMAR

SNPS

TSCO

VEEV

Press Releases

Walgreens Boots Alliance Sells Shares of Cencora for Approximately $1.1 Billion of Proceeds

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Cencora Elects Frank Clyburn to Its Board of Directors

Frazier Healthcare Partners Adds Highly Experienced Pharma Executive to Growth Buyout Team

Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release

Cencora Expands Enterprise Leadership Team with Two Senior Appointments

Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

Cencora Closes $1.8 Billion Senior Notes Offering

AdaptHealth

Akso Health Group - American Depositary Shares

Akso Health

Agape ATP

Cardinal Health

Cosmos Health

Henry Schein

McKesson

Owens & Minor

Patterson Cos

Virax Biolabs Group Limited - Ordinary Shares

Virax Biolabs Group

Wells Fargo

Baird

Barclays

Evercore ISI Group

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">2024년 ESMO 연례 회의</a>에서 발표되었다고 발표했다.
2. Joint Stock Company Kaspi.kz(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>)의 주식이 21.66% 급락했다. 이는 컬퍼 리서치(Culper Research)가 <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이 회사에 대한 공매도 보고서를 발표</a>한 후 주가는 21.66% 하락했다.
3. 바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주식이 16.74% 하락했다. 이는 경쟁사인 아센디스 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)의 <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강력한 왜소증 치료제 데이터</a> 발표 이후 발생한 일이다.
4. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">지난주</a> 13.26% 하락했다.
5. 페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 회사가 예상보다 나쁜 1분기 재무 결과를 보고하고 <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스를 하향 조정</a>한 후 11.08% 하락했다.
6. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식이 9.01% 하락했다. 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)와 바이오엔텍은 유럽 연합에서 오미크론(omicron) KP.2 적응 <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">코로나19 백신</a>에 대해 긍정적인 CHMP 의견을 받았다.
7. 아서 J 갤러거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>)의 주식이 7.17% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>한 후 발생한 일이다.
8. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식이 6.97% 하락했다. 이는 회사가 주식 공모와 <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">동시 주식 매입</a>을 발표한 후 발생한 일이다.
9. 노보 노디스크 A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식은 비만 환자를 대상으로 한 몬루나반트(monlunabant)의 <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중간 단계 연구 결과가 헤드라인</a>을 장식한 후 6.93% 하락했다.
10. 머피 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)의 주식이 6.90% 하락했다. 이는 JP 모건이 주식 등급을 중립에서 비중축소(Underweight)로 하향 조정했지만 <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $415에서 $435로 상향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%98%EC%8A%A4%ED%85%94%EB%A0%88%EC%9D%B4%EC%85%98-%EB%B0%8F-%EC%B9%B4%EB%B0%94%EB%82%98%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">콘스텔레이션 및 카바나는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (9월 16일-9월 20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>내셔널 그리드 트랜스코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGG#NYSE">NGG</a>)가 70억 파운드의 자본금을 늘리고 <a href="https://www.benzinga.com//node/38991860" target="_blank" rel="noreferrer noopener">연간 매출 결과</a>가 전년 대비 감소했다고 보고한 후 주각가 17.1% 급락했다.</li>
<li>제임스 하디 인더스트리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>)의 주가는 회사가 예상보다 나쁜 <a href="https://www.benzinga.com//node/38929144" target="_blank" rel="noopener noreferrer">4분기</a> 실적을 발표한 후 14.4% 하락했다.</li>
<li>KE 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/38981059" target="_blank" rel="noreferrer noopener">1분기 재무 결과를 발표</a>한 후 지난주에 주가가 14% 급락했다.</li>
<li>징동닷컴(JD.Com, Inc.)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/38944001" target="_blank" rel="noreferrer noopener">1분기 중간</a> 실적을 발표하고 15억 달러 규모의 전환선순위채 발행을 제안한 이후 13.70% 하락했다.</li>
<li>XP(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>)의 주식은 회사가 예상보다 나쁜 <a href="https://www.benzinga.com//node/38950599" target="_blank" rel="noreferrer noopener">1분기 EPS</a> 실적을 보고한 후 주가는 13.3% 급락했다.</li>
<li>노드슨 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>)의 주가는 엇갈린 2분기 실적과 약한 3분기 매출 가이던스로 인해 12.3% 하락했으며, 몇몇 <a href="https://www.benzinga.com//node/38966867" target="_blank" rel="noreferrer noopener">분석가들의 전망치를</a> 대폭 낮췄다.</li>
<li>베이진(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>)의 주식은 11.6% 하락했다.</li>
<li>룰루레몬 애틀라티카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NYSE">LULU</a>)의 주식은 선 초 <a href="https://www.benzinga.com//node/38962335">최고 제품 책임자</a>(CPO) 사임 발표 이후 주가는 지난 주 11.3% 하락했다. 회사는 조직개편을 실시할 계획이라고 밝혔다.</li>
<li>월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)의 주가는센코라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) 주식을 4억 달러에 매각한 사실이 <a href="https://www.benzinga.com//node/38975615" target="_blank" rel="noopener">공개</a>된 후 10.80% 하락했으며 소유 지분을 13%에서 12%로 하락했다.</li>
<li>리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주가는 월요일 회사가 예상보다 나쁜 <a href="https://www.benzinga.com//node/38915754">1분기</a> 실적을 발표하고 2분기 전망을 발표한 후 10.40% 하락했다.</li>
</ol>
다른 주요 내용: <a href="https://www.benzinga.com/news/large-cap/24/05/39022913/moderna-was-among-the-best-performing-large-cap-stocks-last-week-may-20-may-26-2024-are-they-in-yo">모더나, 지난 주 가장 좋은 실적을 기록한 대형주들 중 하나였다: 여러분 포트폴리오에도 포함되어 있나요?</a>
사진: Pixabay의 Pedro Alvarez

Comments

Cencora

뉴스

에 대한 최신 뉴스 Cencora (NYSE:COR) 주식

월요일, 9월 23, 2024

일요일, 5월 26, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌